Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 2 Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

NCT04511013 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.

NCT NCT04511013
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04511013 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 2 Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
Lead sponsor
SWOG Cancer Research Network
Phase
Phase 2
Overall status
Recruiting
Start date
January 6, 2021
Completion date
June 30, 2027
Enrollment
112 (estimated)
Sites
331

Conditions

As the registry lists them; a condition with its own page is linked.

acral lentiginous melanoma, clinical stage iv cutaneous melanoma ajcc v8, metastatic cutaneous melanoma, metastatic malignant neoplasm in the brain, metastatic melanoma, metastatic mucosal melanoma, pathologic stage iv cutaneous melanoma ajcc v8